ATP13A2 Hereditary Spastic Paraplegia (SPG78)

ATP13A2 hereditary spastic paraplegia—also called spastic paraplegia type 78 (SPG78)—is a rare, inherited nerve-degeneration disease that mainly stiffens and weakens the legs over time. It usually starts in adulthood, causing trouble with walking because the muscles in the lower limbs become tight (spastic) and weak. Many people also show cerebellar signs (poor balance and coordination), speech problems (dysarthria), abnormal eye movements, and sometimes thinking and memory problems. Brain scans often show shrinkage (atrophy) of the cerebellum. The condition is autosomal recessive, meaning a person develops it when they inherit two harmful changes (variants) in the same gene—one from each parent. The gene involved is ATP13A2, which makes a protein that works inside lysosomes (the cell’s recycling centers) to move small molecules called polyamines across membranes. When ATP13A2 does not work properly, lysosomes and energy factories (mitochondria) become stressed, and nerve cells gradually malfunction and die, leading to the symptoms above. PMC+3NCBI+3orpha.net+3

ATP13A2 hereditary spastic paraplegia is a rare, inherited nerve disorder that mainly stiffens and weakens the legs over time. “Spasticity” means muscles stay too tight; “paraplegia” means the legs are most affected. The ATP13A2 gene helps brain cells handle certain minerals and waste inside tiny compartments called lysosomes. When this gene does not work correctly, some cells in the brain and spinal cord stop working as they should. People develop walking problems, leg stiffness and cramps, and sometimes balance troubles, tremor or parkinsonism, slowness, or thinking changes. Doctors may call this SPG78 or say it is part of the ATP13A2/PARK9 spectrum (which can also include Kufor-Rakeb syndrome). There is no cure yet, but targeted rehab, symptom-based medicines, and assistive devices can greatly improve comfort, safety, and independence. PubMed+2PubMed+2

ATP13A2 is a P5B-type ATPase. In human cells it exports polyamines (especially spermine) from lysosomes to the cytosol, helping keep polyamine levels balanced and lysosomes healthy. Structural biology studies (cryo-EM) have shown how the protein changes shape to perform this transport. When ATP13A2 is damaged, polyamine handling, lysosomal function, and mitochondrial health are disturbed, which is thought to drive the nerve damage seen in SPG78 and related disorders. UniProt+3Nature+3Nature+3

---

Other names

• Spastic paraplegia type 78; SPG78

• ATP13A2-related hereditary spastic paraplegia

• Autosomal recessive spastic paraplegia-78

• ATP13A2-HSP
  (These all refer to HSP caused by ATP13A2 variants.) National Organization for Rare Disorders+1

Note: The same gene can also cause Kufor-Rakeb syndrome (PARK9), an early-onset parkinsonism with dementia. Some patients sit on a spectrum, with either parkinsonism-dominant or spasticity-dominant disease. PMC+1

---

Types

Doctors don’t use one universal “type” list for SPG78, but they commonly group patients by clinical pattern, age at onset, and genetic/functional features. Here are practical “types” you may read about:

1. Pure vs. complicated HSP
   Pure HSP means mainly leg spasticity/weakness. Complicated HSP adds other features such as ataxia, speech problems, eye movement issues, cognitive decline, parkinsonism, or peripheral nerve involvement. ATP13A2-HSP is often complicated, but “pure” cases have been reported. OUP Academic+1

2. Adult-onset vs. childhood/juvenile-onset
   Most SPG78 patients develop symptoms in adulthood; younger onset is less common but part of the spectrum of ATP13A2 disease. NCBI

3. Spasticity-dominant vs. parkinsonism-dominant spectrum
   Some ATP13A2 patients look like Kufor-Rakeb syndrome (PARK9) with early parkinsonism, while others have spasticity with cerebellar features (SPG78). A few have both. PMC+1

4. By gene variant class
   Variants include missense, nonsense/frameshift, and splice changes. Loss-of-function variants tend to disrupt the protein’s catalytic activity and trafficking. OUP Academic

5. By imaging phenotype
   Many show cerebellar atrophy; some also have cortical or brainstem changes. NCBI

---

Causes

Strictly speaking, the root cause is pathogenic variants in the ATP13A2 gene. Below are 20 disease-driving factors and mechanisms—all tied to how ATP13A2 failure harms nerve cells. Each item is described in simple language.

1. Biallelic ATP13A2 variants (autosomal recessive inheritance)
   Two harmful variants (one from each parent) are needed to produce disease. NCBI

2. Loss of ATP13A2 transport activity
   Damaged protein cannot move polyamines efficiently, disturbing lysosomal chemistry. OUP Academic

3. Polyamine imbalance
   When polyamines (e.g., spermine) are not handled properly, many cell processes, including protein synthesis and stress responses, go wrong. Nature+1

4. Lysosomal dysfunction
   Lysosomes recycle worn-out cell parts. If they fail, toxic waste builds up and stresses neurons. PMC

5. Mitochondrial stress
   Energy production is impaired; neurons are energy-hungry and highly sensitive to this. OUP Academic

6. Impaired autophagy
   Cells have trouble clearing damaged proteins and organelles, leading to further toxicity. PMC

7. Oxidative stress
   Reactive oxygen species rise when lysosomes and mitochondria misbehave, damaging cell components. PMC

8. Abnormal ion/homeostasis signaling
   Polyamines modulate channels and signaling; imbalance can alter neuronal firing and survival. Nature

9. Protein misfolding burden
   Inefficient clearance increases misfolded proteins that clog cellular systems. PMC

10. Endolysosomal membrane stress
    Traffic and membrane composition changes make recycling compartments leaky or sluggish. PMC

11. Synaptic dysfunction
    Energy failure and trafficking problems disturb neurotransmitter release and uptake. (Mechanistic inference from lysosomal/mitochondrial roles in neurons.) PMC

12. Axonal transport problems
    Long motor pathways need smooth transport; cellular stress slows it, harming corticospinal tracts. (Mechanistic inference grounded in HSP biology.) OUP Academic

13. Neuroinflammation secondary to debris accumulation
    Poor clearance can trigger inflammatory cascades that worsen injury. PMC

14. Selective vulnerability of upper motor neurons
    These long neurons are especially exposed to autophagy/energy defects. (Inference consistent with HSP pathophysiology.) OUP Academic

15. Cerebellar neuron susceptibility
    Explains ataxia and cerebellar atrophy on MRI. NCBI

16. Modifier variants in other genes (e.g., LRRK2 context)
    ATP13A2 variation can modify features in other PD-gene settings, hinting at genetic modifiers. Frontiers

17. Trafficking/quality-control defects of mutant ATP13A2
    Some variants mislocalize or destabilize the protein, reducing function. OUP Academic

18. Impaired cellular response to heavy metals or toxins
    Lysosomal stress reduces the cell’s capacity to buffer stressors. (Mechanistic theme in ATP13A2 literature.) PMC

19. Neuronal circuit disconnection
    Progressive degeneration disrupts corticospinal and cerebellar circuits. (Clinical–anatomic correlation.) NCBI

20. Time (progression)
    Slow, ongoing degeneration over years produces worsening stiffness, weakness, and balance problems. NCBI

---

Symptoms and signs

Each item below is written in simple words, then linked to what doctors see.

1. Stiff legs (spasticity)
   Leg muscles feel tight; steps are short and scissoring; legs resist passive stretch. Doctors find increased tone and catch on exam. NCBI

2. Leg weakness
   Climbing stairs and rising from chairs become hard. Strength testing shows pyramidal-pattern weakness. NCBI

3. Gait trouble and falls
   Walking becomes slow and unsteady; feet may drag; falls increase over time. NCBI

4. Overactive reflexes
   Knee and ankle jerks are brisk; Babinski signs (toe-up) may appear. NCBI

5. Cerebellar ataxia
   Poor balance and clumsy limb movements; difficulty with heel-to-shin and finger-to-nose tests. MRI often shows cerebellar atrophy. NCBI

6. Dysarthria (slurred speech)
   Speech sounds “scanned” or slurred due to cerebellar and corticobulbar involvement. NCBI

7. Abnormal eye movements
   Nystagmus or pursuit/saccade problems; patients describe “jerky eyes” or blurred tracking. NCBI

8. Cognitive issues
   Mild memory or planning problems; occasionally dementia is reported. NCBI

9. Leg cramps and spasms
   Painful tightening, especially at night, from spastic muscles. (Common in HSP.) OUP Academic

10. Urinary urgency/spastic bladder
    Needing to pass urine quickly or frequently due to upper motor neuron involvement. (Reported in complicated HSP.) OUP Academic

11. Fatigue with walking
    Effort increases as stiffness and weakness progress. (Typical HSP experience.) OUP Academic

12. Parkinsonism in some patients
    Slowness (bradykinesia), stiffness, and reduced arm swing may occur, reflecting ATP13A2’s broader spectrum (PARK9). PMC

13. Dystonia (in a subset)
    Involuntary twisting postures can appear with complicated disease. OUP Academic

14. Peripheral neuropathy signs (occasional)
    Numbness/tingling or reduced vibration sense in some complicated forms. OUP Academic

15. Slow progression
    Symptoms usually advance over years; some people eventually need aids or a wheelchair. NCBI

---

Diagnostic tests

Doctors diagnose ATP13A2-HSP by combining clinical signs, neuroimaging, and genetic testing. The list below is grouped by category. Each test is explained in very plain language.

A) Physical examination

1. Neurological motor exam
   The doctor checks tone, power, and reflexes in the legs. Spasticity, weakness, brisk reflexes, and Babinski signs support upper motor neuron disease. This steers testing toward HSP. NCBI

2. Gait observation
   Watching you walk shows a stiff, scissoring pattern with poor foot clearance. Progression over time supports a degenerative spastic paraparesis. NCBI

3. Cerebellar testing
   The doctor checks finger-to-nose, heel-to-shin, and rapid alternating movements. In SPG78, these are often clumsy, pointing to cerebellar involvement. NCBI

4. Eye movement exam
   Saccades and pursuit are checked. Abnormalities hint at cerebellar/brainstem involvement common in complicated SPG78. NCBI

5. Cognitive screening
   Short memory and executive tests (e.g., MoCA) can reveal subtle impairment; some patients have more severe deficits. NCBI

B) Bedside/manual tests

6. Timed walking tests (e.g., 10-meter walk)
   Simple timed walks track speed and functional change over visits, quantifying progression. (Standard HSP practice.) OUP Academic

7. Romberg test
   Standing with feet together, eyes closed helps detect sensory or cerebellar balance problems that accompany spastic gait. NCBI

8. Pull test / postural stability
   A gentle backward tug checks for retropulsion (a parkinsonian sign) in patients who have ATP13A2-spectrum features. PMC

9. Nine-Hole Peg Test / finger tapping
   Hand speed/coordination testing may show subtle cerebellar or parkinsonian issues, even when legs dominate the picture. PMC

10. Spasticity scales (e.g., Modified Ashworth Scale)
    These bedside ratings document how tight the muscles are and whether treatment is helping. (Widely used spasticity measure.) OUP Academic

C) Laboratory and pathological tests

11. Comprehensive genetic testing (ATP13A2 sequencing or exome/genome)
    This is the definitive test. It looks for two disease-causing ATP13A2 variants. Finding them confirms autosomal recessive SPG78 when the clinical picture matches. OUP Academic

12. Segregation testing in family members
    Testing parents/siblings shows each parent carries one variant (carriers) and helps with counseling. NCBI

13. Variant interpretation (ACMG/AMP criteria)
    Bioinformatic and laboratory evidence classifies variants (pathogenic/likely pathogenic). This step turns raw findings into a clinical diagnosis. OUP Academic

14. Rule-out blood tests
    Vitamins (B12/E), thyroid, copper, syphilis, HIV, autoimmune markers—done to exclude other treatable causes of spastic paraparesis/ataxia before concluding genetic HSP. (Standard HSP work-up.) OUP Academic

15. (Research) functional assays of ATP13A2
    Specialized labs can measure polyamine transport in model systems, supporting causality for novel variants; this is not routine clinical testing. en.bio-protocol.org

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS)
    Looks for neuropathy if numbness/tingling are present. Many SPG78 patients have normal NCS; abnormal results suggest a “complicated” picture. OUP Academic

17. Electromyography (EMG)
    Checks for muscle denervation or other patterns that might point away from pure upper motor neuron disease. Helpful in differential diagnosis. OUP Academic

18. Evoked potentials (e.g., motor evoked potentials)
    Can show slowed conduction in central motor pathways, supporting corticospinal tract involvement. (Ancillary HSP test in some centers.) OUP Academic

E) Imaging tests

19. Brain MRI
    Frequently shows cerebellar atrophy and sometimes other changes. This supports a complicated HSP and helps rule out other causes. NCBI

20. Spine MRI
    Usually normal in genetic HSP; it helps exclude compression, inflammation, or structural spine disease that could mimic spastic paraparesis. (Standard HSP evaluation.) OUP Academic

Non-pharmacological treatments (therapies and others)

1. Physiotherapy for spasticity and strength
   Daily, guided stretching and range-of-motion keep joints from getting stiff and reduce cramps. Task-specific gait training (practicing real-world walking tasks), strengthening of antigravity muscles, and balance drills lower fall risk. Therapists use contract-relax stretches, sustained holds, and home programs matched to your goals. They also teach safe transfer techniques, fall-recovery, and energy conservation. Expect gradual gains: better step length, easier turning, and less night spasm. Combining therapy with medications or botulinum toxin gives stronger results than any one method alone. Purpose: ease stiffness, keep joints moving, improve safe walking. Mechanism: repeated, slow stretching lowers the muscle’s stretch-reflex “over-response,” while strength and balance training improve how nerves recruit muscles and how the brain plans movement. rcp.ac.uk+1

2. Home stretching program
   A simple daily routine—hamstrings, calves, hip flexors, adductors—done slowly (30–60 seconds per hold, 3–5 repetitions) helps keep muscle length. Use a strap or wall for leverage. Pair stretching with heat or a warm shower for comfort. Purpose: maintain range, reduce spasms and pain. Mechanism: sustained stretch dampens spinal reflex excitability and decreases muscle spindle sensitivity over time. rcp.ac.uk

3. Gait training with assistive devices
   A cane, crutch, or walker can stabilize turns and uneven ground. Therapists fit devices and teach cadence, step width, and turning strategies. Purpose: reduce falls, increase distance and confidence. Mechanism: wider base of support lowers the torque demands at spastic hips/knees; external support reduces compensations that worsen spasticity. rcp.ac.uk

4. Ankle-foot orthoses (AFOs)
   Light plastic braces hold the ankle at neutral to prevent toe drag and knee buckling. Hinged AFOs allow some ankle motion; solid AFOs maximize stability. Purpose: safer foot clearance, steadier stance, less fatigue. Mechanism: mechanical positioning reduces stretch triggers on calf muscles and keeps the ground reaction force in a safer line with the knee. rcp.ac.uk

5. Functional electrical stimulation (FES)
   Surface electrodes cue the tibialis anterior to lift the toes during swing phase, timed to your step. Purpose: reduce tripping from foot drop. Mechanism: brief current activates the dorsiflexors at the right moment, replacing weak neural drive. rcp.ac.uk

6. Occupational therapy (OT) for daily living
   OT teaches dressing with spastic legs, bathroom safety, kitchen reach strategies, and energy pacing. Home modifications (grab bars, raised toilet seat) reduce effort. Purpose: independence and safety. Mechanism: task-oriented training rewires planning pathways and cuts risky leverage that provokes spasms. rcp.ac.uk

7. Speech-language therapy (if dysarthria or swallowing issues)
   Therapists work on breath support, slower speech rate, and clear articulation; for swallowing, texture adjustments and safe-swallow strategies. Purpose: clearer communication; prevent choking/aspiration. Mechanism: repetitive motor practice strengthens oropharyngeal coordination and compensations. rcp.ac.uk

8. Bladder training and pelvic-floor therapy
   Urgency or frequency can accompany spasticity. Timed voiding, fluids scheduling, and pelvic-floor relaxation help. Purpose: fewer accidents, better sleep. Mechanism: behavioral timing and relaxation reduce detrusor overactivity triggers. SpringerLink

9. Heat, gentle massage, and positioning
   Warm packs before stretching and proper nighttime positioning ease spasms. Purpose: comfort, better sleep. Mechanism: warmth reduces alpha-motor neuron excitability; neutral joint positions reduce reflex triggers. rcp.ac.uk

10. Pain self-management education
    Breathing, pacing, and sleep hygiene cut pain-spasm cycles. Purpose: less pain, better function. Mechanism: improved central pain gating and lower stress-related sympathetic drive. PMC

11. Fall-prevention plan
    Home hazard audit (rugs, cords), night lights, sturdy shoes, and “turn-pause-step” technique. Purpose: fewer injuries. Mechanism: environmental control + safer movement patterns reduce perturbations that trigger spasticity. rcp.ac.uk

12. Hydrotherapy
    Warm-water walking lessens gravity load and allows smoother steps. Purpose: safer practice, less stiffness. Mechanism: buoyancy reduces extensor co-contraction; warmth calms reflexes. rcp.ac.uk

13. Task-oriented treadmill or over-ground training
    Short bouts with rests, speed adjusted to safe cadence. Purpose: re-learn steady gait. Mechanism: repetitive stepping normalizes central pattern generators and stretch-reflex thresholds. rcp.ac.uk

14. Constraint and cueing for freezing or parkinsonism
    Visual lines, metronome beats, and external cues help initiate steps. Purpose: smoother starts/turns. Mechanism: cues bypass impaired internal timing with external stimuli. PubMed

15. Energy conservation and fatigue management
    Plan tasks, cluster errands, and schedule rests. Purpose: more done with fewer flares. Mechanism: limits spasticity triggers from overuse and central fatigue. rcp.ac.uk

16. Pressure-relief and skin care
    Cushions and turning schedules protect heels and sacrum when mobility drops. Purpose: prevent sores. Mechanism: off-loading reduces ischemia and microtrauma. rcp.ac.uk

17. Orthopedic seating and wheelchairs (when needed)
    Proper seat depth, cushion, and back support reduce tone and pain on long outings. Purpose: safe community mobility. Mechanism: biomechanical alignment limits reflex triggers. rcp.ac.uk

18. Community exercise (cycling, gentle yoga, tai chi)
    Low-impact movement sustains flexibility and balance. Purpose: maintain endurance and mood. Mechanism: repeated slow ROM and postural control recalibrate tone. rcp.ac.uk

19. Caregiver training
    Safe transfers, stretching assist, device setup. Purpose: fewer injuries, consistent care. Mechanism: correct handling avoids noxious stimuli that raise tone. rcp.ac.uk

20. Genetic counseling
    Explains inheritance, family testing, and planning. Purpose: informed choices for relatives. Mechanism: clarifies autosomal-recessive risk and testing pathways. PubMed

---

Drug treatments

Important: No medicine cures ATP13A2-related HSP. The drugs below treat symptoms commonly seen in HSP—especially spasticity and, in some people, parkinsonism, pain, or bladder urgency. Doses are typical label ranges; your doctor individualizes them.

1. Baclofen (oral)
   Class: GABA-B agonist antispastic. Dose/Time: Often start 5 mg three times daily; gradually increase; many adults respond between 30–80 mg/day in divided doses. Purpose: reduce muscle tone, cramps, and spasms. Mechanism: stimulates spinal GABA-B receptors, inhibiting excitatory neurotransmission in the stretch reflex arc. Side effects: sleepiness, weakness, dizziness; do not stop suddenly (withdrawal). Evidence: Widely used first-line for spasticity; label details dosing and cautions. PMC

2. Baclofen (intrathecal)—LIORESAL® INTRATHECAL (pump infusion)
   Class: GABA-B agonist delivered to cerebrospinal fluid. Dose/Time: Screening bolus first; then implanted pump with programmable continuous infusion; dose titrated by specialists. Purpose: severe generalized spasticity not controlled by pills. Mechanism: high spinal concentrations with lower systemic exposure. Side effects: hypotonia (too much looseness), drowsiness; pump/catheter risks. Evidence/Label: Indicated for severe spasticity; labeling covers screening, titration, and safety. FDA Access Data

3. Tizanidine (ZANAFLEX®)
   Class: α2-adrenergic agonist antispastic. Dose/Time: Commonly start 2 mg up to three times daily; increase slowly; max around 36 mg/day. Purpose: decrease tone and spasm frequency. Mechanism: reduces excitatory input to motor neurons. Side effects: sleepiness, dry mouth, low blood pressure; taper to avoid rebound hypertension. Evidence/Label: FDA label details hypotension risk and titration. FDA Access Data+1

4. Dantrolene (DANTRIUM® capsules)
   Class: peripheral muscle relaxant. Dose/Time: Often start 25 mg/day; slowly increase; maintenance commonly 25–100 mg three or four times daily; max 400 mg/day. Purpose: lower spastic muscle contractions when centrally acting agents aren’t tolerated. Mechanism: reduces calcium release from sarcoplasmic reticulum, weakening excessive contraction. Side effects: liver toxicity risk, weakness, dizziness—requires monitoring. Evidence/Label: Hepatotoxicity warnings and dose ranges in FDA label. FDA Access Data

5. Diazepam
   Class: benzodiazepine (antispastic/anxiolytic). Dose/Time: Low bedtime dosing (e.g., 2–5 mg) may help night spasms; daytime use limited by sedation. Purpose: short-term spasm relief, especially nocturnal cramps. Mechanism: enhances GABA-A inhibition. Side effects: sedation, falls, dependence; tapering needed. Evidence: Guideline documents list diazepam as licensed for spasticity in some regions; clinicians use cautiously. rcp.ac.uk

6. OnabotulinumtoxinA (BOTOX®) — focal spasticity
   Class: neuromuscular blocker. Dose/Time: Units and muscles individualized; typically reinjected about every 12 weeks. Purpose: relax overactive focal muscles (adductors, calves) to improve gait, brace fit, and hygiene. Mechanism: blocks acetylcholine release at neuromuscular junction. Side effects: local weakness, pain; rare spread-of-toxin symptoms. Evidence/Label: FDA labeling recognizes use in adult limb spasticity and dosing principles. FDA Access Data+1

7. Carbidopa/Levodopa (SINEMET®; SINEMET® CR)
   Class: dopaminergic combination for parkinsonism. Dose/Time: Start low (e.g., 25/100 mg ½–1 tablet 2–3×/day) and titrate; CR version extends effect. Purpose: for patients within the ATP13A2 spectrum who show parkinsonian slowness, rigidity, or freezing. Mechanism: levodopa converts to dopamine; carbidopa prevents peripheral breakdown. Side effects: nausea, low blood pressure, dyskinesia with higher/long-term dosing. Evidence/Label: FDA labels detail dosing and cautions. FDA Access Data+1

8. Amantadine
   Class: dopaminergic/NMDA-modulating agent. Dose/Time: Commonly 100 mg once or twice daily; ER versions exist. Purpose: may help fatigue, parkinsonism, or dyskinesia in some patients. Mechanism: increases dopamine release and modulates glutamate. Side effects: ankle swelling, livedo reticularis, insomnia. Evidence/Label: FDA-approved for Parkinson’s disease formulations; clinicians individualize off-label symptom use in HSP with parkinsonism features. FDA Access Data

9. Trihexyphenidyl (Artane®)
   Class: anticholinergic. Dose/Time: Often 1 mg/day, titrating slowly to the lowest helpful dose (commonly up to ~6–10 mg/day divided). Purpose: may lessen dystonia or tremor components when present. Mechanism: reduces cholinergic-dopaminergic imbalance. Side effects: dry mouth, constipation, confusion (caution in older adults). Evidence: long-standing use in parkinsonism on FDA-labeled products. FDA Access Data

10. Clonazepam (Klonopin®)
    Class: benzodiazepine. Dose/Time: 0.25–0.5 mg at night, titrating cautiously. Purpose: reduce nocturnal myoclonus or severe night spasms. Mechanism: GABA-A enhancement. Side effects: sedation, imbalance, tolerance. Evidence: labeled for seizure/panic; used off-label in spasticity-related myoclonus when benefits outweigh risks. rcp.ac.uk

11. Gabapentin (Neurontin®)
    Class: α2δ calcium-channel modulator. Dose/Time: Start 300 mg at night, increase to 300 mg three times daily; higher doses often needed for neuropathic pain. Purpose: neuropathic leg pain or paresthesias that can accompany HSP. Mechanism: reduces excitatory neurotransmission via calcium-channel modulation. Side effects: dizziness, drowsiness, edema. Evidence/Guidance: appears in spasticity management resources as adjunct when pain amplifies tone. rcp.ac.uk+1

12. Pregabalin (Lyrica®)
    Class: α2δ calcium-channel modulator. Dose/Time: 75 mg twice daily, titrating to 150–300 mg twice daily as tolerated. Purpose: neuropathic pain and sleep improvement. Mechanism: dampens excitatory neurotransmitter release. Side effects: dizziness, weight gain, edema. Evidence: widely used for neuropathic pain that worsens spasms. rcp.ac.uk

13. Duloxetine (Cymbalta®)
    Class: SNRI antidepressant/neuropathic pain agent. Dose/Time: 30 mg daily ×1 week, then 60 mg daily; adjust to response. Purpose: neuropathic pain and mood symptoms that can amplify spasticity. Mechanism: increases serotonin/norepinephrine to modulate descending pain pathways. Side effects: nausea, dry mouth, sleep changes; rare BP effects. Evidence: FDA-approved for neuropathic pain and depression; note periodic quality-control recalls of specific lots reported in news—patients should not stop abruptly and should consult clinicians if affected. Health+2People.com+2

14. Oxybutynin (Ditropan®/XL)
    Class: antimuscarinic for bladder urgency. Dose/Time: 2.5–5 mg 2–3×/day (IR) or 5–10 mg daily (ER), titrate to effect. Purpose: overactive bladder symptoms common in spastic disorders. Mechanism: reduces detrusor overactivity. Side effects: dry mouth, constipation. Evidence: standard FDA-labeled therapy for urgency/frequency. SpringerLink

15. OnabotulinumtoxinA for adductors/calf overactivity
    Class: see #6; here targeted to gait-limiting muscles. Dose/Time: injection patterns individualized; effects last ~3 months. Purpose: improve step clearance, brace tolerance, hygiene. Mechanism: local chemodenervation. Side effects: localized weakness; follow dosing limits per label. Evidence: established effectiveness for adult limb spasticity in multiple high-level studies and practice guidelines. PMC+1

16. Bowel regimen medications (as needed)
    Class: osmotic/stimulant laxatives (e.g., polyethylene glycol, senna). Dose/Time: individualized. Purpose: treat constipation that worsens spasms and discomfort. Mechanism: soften stool and promote motility. Evidence: standard symptomatic care in spasticity guidelines. rcp.ac.uk

17. Analgesics (acetaminophen/NSAIDs, with caution)
    Class: pain relievers. Dose/Time: as labeled, with liver/renal/GI precautions. Purpose: break pain-spasm cycle. Mechanism: central prostaglandin and peripheral anti-inflammatory actions. Evidence: supportive symptomatic role in musculoskeletal pain within spasticity care. rcp.ac.uk

18. Sleep aids (short-term, cautious)
    Class: melatonin or carefully selected sedating agents. Dose/Time: lowest effective dose, short duration. Purpose: improve sleep to reduce daytime tone. Mechanism: better sleep lowers sympathetic drive and pain sensitivity. Evidence: adjunctive role in comprehensive programs. rcp.ac.uk

19. Antidepressants for mood (if present)
    Class: SSRIs/SNRIs per label. Dose/Time: individualized. Purpose: treat depression/anxiety that amplify pain and disability. Mechanism: neurotransmitter modulation improves coping and reduces central sensitization. Evidence: standard mental-health care within neurorehab. rcp.ac.uk

20. Spasticity care “combination therapy”
    Class: carefully combined low-dose agents (e.g., baclofen + botulinum toxin + therapy). Dose/Time: staged titration to minimize side effects. Purpose: achieve tone control with fewer adverse effects. Mechanism: complementary central and focal actions. Evidence: recommended approach in expert guidelines for adult spasticity. rcp.ac.uk+1

Note: Myobloc® (rimabotulinumtoxinB) is FDA-labeled for cervical dystonia and sialorrhea—not limb spasticity; adult spasticity evidence supports botulinum toxin type A preparations for limbs. FDA Access Data+1

---

Dietary molecular supplements

1. Magnesium — May reduce nocturnal cramps and improve relaxation. Dose: often 200–400 mg elemental Mg nightly (adjust for kidney function). Function/Mechanism: cofactor in neuromuscular transmission; mild NMDA antagonism can calm over-excited motor reflexes. Evidence in spasticity is supportive but not definitive; monitor for diarrhea.

2. Vitamin D — Correct deficiency to support muscle strength and balance. Dose: typical 1000–2000 IU/day (or per lab-guided repletion). Mechanism: nuclear receptor effects in muscle; deficiency links to falls.

3. Omega-3 fatty acids (EPA/DHA) — Dose: ~1–2 g/day combined EPA+DHA with meals. Mechanism: anti-inflammatory membrane effects; may help joint discomfort and general cardiovascular health that supports rehab tolerance.

4. Coenzyme Q10 — Dose: 100–200 mg/day. Mechanism: mitochondrial electron transport support; might reduce fatigue.

5. Alpha-lipoic acid — Dose: 300–600 mg/day. Mechanism: antioxidant; may help neuropathic symptoms in diabetes and could modestly aid nerve comfort.

6. Acetyl-L-carnitine — Dose: 500–1000 mg 2–3×/day. Mechanism: supports mitochondrial fatty-acid transport; sometimes used for neuropathic pain and fatigue.

7. Creatine monohydrate — Dose: 3–5 g/day. Mechanism: phosphocreatine energy buffer; may assist resistance training response and reduce perceived exertion.

8. Curcumin (with piperine or formulated for absorption) — Dose: per product (often 500–1000 mg/day). Mechanism: NF-κB modulation; may help low-grade inflammatory pain.

9. B-complex (esp. B12, B6, folate as needed) — Dose: per label; replete documented deficiencies. Mechanism: supports myelin synthesis and nerve metabolism.

10. Probiotics/fiber (psyllium, inulin) — Dose: 5–10 g/day fiber (add slowly). Mechanism: gut-motility and stool-softening to ease constipation that worsens spasticity.

These are adjuncts, not treatments for the gene disorder. Coordinate with your clinician, especially if you take anticoagulants, have kidney disease, or are pregnant.

---

Immunity-booster / Regenerative / Stem-cell” drugs

At present, there are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for ATP13A2-related HSP. What follows are research-oriented or supportive categories, not prescriptions.

1. Vaccinations (standard adult schedule) — keeping up to date reduces infection stress that can spike spasticity and hospitalizations. Dose: per national schedule. Function/Mechanism: primes immune memory to prevent illness.

2. Vitamin D repletion (if deficient) — immune-modulating and muscle-supportive. Dose: lab-guided. Mechanism: steroid-like effects on immune cells and muscle.

3. Physical conditioning as “immune training” — regular moderate exercise improves innate and adaptive responses. Dose: most days, 20–40 minutes adapted to ability. Mechanism: anti-inflammatory myokines and improved lymph flow.

4. Investigational cell therapies — in some neuro disorders, clinical trials test mesenchymal or neural progenitor cells. Dose: trial-defined. Mechanism: proposed trophic and anti-inflammatory effects. Status: experimental—not standard of care.

5. Neurotrophic-pathway enhancers (research stage) — agents that target lysosome-autophagy or mitochondrial quality control are being studied across neurodegeneration. Mechanism: improve cellular waste handling relevant to ATP13A2 biology. Status: early research.

6. Edaravone or other oxidative-stress modulators (contextual note) — approved for other motor neuron disease, sometimes discussed off-label for neuroprotection; not established for HSP. Mechanism: free-radical scavenging. Status: off-label, evidence insufficient in HSP.

Because claims in this area are often overstated, discuss any “regenerative” product with your neurologist and consider clinical trials at academic centers.

---

Surgeries / procedures

1. Intrathecal baclofen pump implantation
   Procedure: a small pump is placed under abdominal skin; a catheter delivers baclofen into spinal fluid. After a test dose, surgeons implant the device under general or regional anesthesia. The pump is refilled every few months. Why done: for severe generalized spasticity when pills and focal injections are not enough or cause too many side effects; the pump targets the spinal cord directly with lower body-wide side effects. FDA Access Data

2. Botulinum toxin injection sessions (focal chemodenervation)
   Procedure: ultrasound or EMG-guided injections into overactive muscles (e.g., hip adductors, gastrocnemius). Sessions repeat about every 12 weeks. Why done: to relax specific muscles that block gait training, hygiene, or brace use. FDA Access Data

3. Soft-tissue lengthening (orthopedic releases)
   Procedure: orthopedic surgeons lengthen tight tendons (e.g., Achilles, hamstrings) when fixed contractures limit walking or hygiene despite therapy/injections. Why done: restore neutral joint position and reduce skin breakdown.

4. Neurolytic procedures (phenol/alcohol blocks)
   Procedure: targeted chemical nerve blocks to reduce tone in a focal pattern when botulinum toxin is not available or unsuitable. Why done: longer-lasting focal tone reduction to improve care and comfort.

5. Selective dorsal rhizotomy (rare in adults with HSP)
   Procedure: neurosurgeons section selected sensory rootlets to lower spasticity. Why done: considered in severe, refractory cases after exhaustive conservative options; candidacy is very selective and evidence in adult HSP is limited.

---

Preventions

1. Keep a daily stretching routine.

2. Use devices (AFO, cane, walker) early to prevent falls.

3. Schedule therapy “tune-ups” to adjust your program.

4. Footwear with good grip and ankle support.

5. Home safety: remove loose rugs, add grab bars and lighting.

6. Bowel/bladder routines to avoid complications that spike tone.

7. Hydration and fiber to prevent constipation.

8. Vaccinations and hand-hygiene to prevent infections.

9. Energy pacing to limit fatigue-induced spasm.

10. Regular follow-up with neurology/rehab to adapt the plan. rcp.ac.uk

---

When to see a doctor (red flags)

• Sudden worsening spasticity, new severe weakness, or repeated falls.

• Fever, urinary symptoms, chest infection, or dehydration that quickly worsens tone.

• Painful, hot, or swollen leg (possible DVT) or new severe back pain.

• Trouble swallowing, choking, or weight loss.

• New cognitive changes, hallucinations, or severe sleepiness (could be medication side effects).

• Pump alarms, catheter pain, or withdrawal symptoms if you have an intrathecal pump. FDA Access Data

---

What to eat and what to avoid

• Eat: lean proteins (eggs, fish, legumes) to support muscle repair—pair with vegetables and whole grains for steady energy.

• Eat: fiber-rich foods (oats, beans, berries) and fluids to prevent constipation that worsens spasticity.

• Eat: potassium- and magnesium-containing foods (leafy greens, bananas, nuts) unless you have kidney issues.

• Eat: omega-3 sources (fatty fish, flax) for general anti-inflammatory support.

• Eat: calcium + vitamin D foods (dairy or fortified alternatives) for bone health if mobility is limited.

• Avoid: excess alcohol (falls, worse tone, drug interactions).

• Avoid: very high-sugar snacks that crash energy.

• Avoid: dehydration—set water reminders.

• Avoid: large late-night caffeine if sleep is fragile.

• Avoid: constipating patterns (low fiber, low fluids).

---

Frequently asked questions

1. Is ATP13A2 HSP the same as Kufor-Rakeb?
   They share the same gene and form a spectrum. Some people mainly have leg spasticity (SPG78); others have more parkinsonism and eye-movement problems (Kufor-Rakeb). PubMed+1

2. Will it get worse?
   HSP usually progresses slowly over years. The pace varies. Good rehab, fall-prevention, and symptom control preserve function longer. PMC

3. Is there a cure?
   Not yet. Care focuses on function and comfort. Research explores lysosomal and mitochondrial pathways related to ATP13A2. PubMed

4. What helps most day to day?
   A consistent stretching/physio routine, the right braces or device, and targeted medicines (e.g., baclofen, tizanidine, or botulinum toxin). rcp.ac.uk+1

5. Are botulinum toxin injections safe?
   When done by trained clinicians, they are generally safe and effective for focal limb spasticity. Effects wear off in ~3 months and dosing is personalized. PMC

6. When is a baclofen pump considered?
   For severe, widespread spasticity when pills and injections fail or cause too many side effects. A screening test checks response before implantation. FDA Access Data

7. Can I drive?
   Discuss with your clinician and, if needed, a driving assessment. Devices and therapy may help reaction time and pedal control.

8. What about pregnancy?
   Plan ahead with neurology and obstetrics. Some drugs used for spasticity are not ideal in pregnancy; alternatives may be needed (risk–benefit discussion essential).

9. Do I need genetic counseling?
   Yes—ATP13A2 conditions are often autosomal recessive; counseling helps family planning and testing options. PubMed

10. Will exercise worsen my spasticity?
    Gentle, regular exercise usually reduces spasticity over time; sudden, intense bursts can briefly worsen it. Pace and cool-down help. rcp.ac.uk

11. Does diet matter?
    There’s no disease-specific diet, but fiber, fluids, and adequate protein help mobility, bowel health, and training tolerance. See diet section above.

12. What about supplements?
    Some people find symptom relief (e.g., magnesium for cramps). Evidence is mixed; coordinate with your clinician to avoid interactions.

13. Can mood or sleep affect spasticity?
    Yes—stress, pain, and poor sleep can raise tone. Treating mood and sleep improves daily control. rcp.ac.uk

14. Are there clinical trials?
    Trials change over time; ask your neurologist or check research registries at academic centers for neurorehabilitation or rare-disease studies.

15. How do I choose between baclofen and tizanidine?
    Both are standard. Baclofen is often first-line; tizanidine is an alternative or add-on. Side-effect profiles differ (e.g., tizanidine can lower blood pressure). Your doctor tailors dosing and combinations. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.